What is the 13F Pro Quality Score for INDV?

13F Pro ranks Indivior Pharmaceuticals, Inc. (INDV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INDV's current score at https://13fpro.ai/company/INDV (free sign-up required for the full ranking).

Where does 13F Pro source INDV data?

All Indivior Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Indivior Pharmaceuticals, Inc. files with the SEC under CIK 1625297. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INDV in?

Indivior Pharmaceuticals, Inc. (INDV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives INDV's revenue?

Per Indivior Pharmaceuticals, Inc.'s latest 10-Q filed with the SEC on 2026-08-03, the biggest revenue drivers are: Total U.S. ($300M, +17% YoY); SUBLOCADE ($238M, +22% YoY); Sublingual & other (Film/other) ($57M, +10% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/INDV.

What are INDV's largest expenses?

Indivior Pharmaceuticals, Inc.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($122M, -23% YoY); Cost of sales ($50M, -3% YoY); Research and development ($12M, -42% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is INDV research updated on 13F Pro?

INDV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Indivior Pharmaceuticals, Inc.(INDV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1625297 INDV stock profile & AI dashboard →

13F Pro Quality Score

58.5/100

Rank #1,006 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

43.1/100

Profitability

89.9/100

Balance Sheet

97.9/100

Earnings Quality

45.6/100

Free Cash Flow

17.8/100

Institutional Flow

81.4/100

Revenue Scale

55.5/100

Dilution Risk

39.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why INDV Scores 59/100

exact factor attribution · 2026-09-11

INDV's composite is driven by profitability and capital efficiency, held back by free cash flow and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+6.0 pts

90th pct

Capital efficiency

+4.8 pts

98th pct

Earnings growth

+2.5 pts

100th pct

Institutional flow

+1.6 pts

81th pct

Scale

+0.8 pts

56th pct

Earnings quality

-0.4 pts

46th pct

Shareholder dilution

-0.5 pts

40th pct

Revenue growth

-1.4 pts

43th pct

Free cash flow

-4.8 pts

18th pct

Latest change (2026-08-03): 65 → 70 · ↑ Profit margin 79→91

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

INDV Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Indivior Pharmaceuticals, Inc. (INDV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INDV at 58.5/100 on a 32-signal composite quality model, placing it at rank #1,006 of 2,961 stocks — the top half of the AI-ranked universe. INDV scores in the top quartile across balance sheet strength (97.9), profitability (89.9), institutional flow (81.4). Areas of concern include free cash flow (17.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Indivior Pharmaceuticals, Inc. reports quarterly revenue of $343.0M, net income of $122.0M, free cash flow of $222.0M. Top institutional holders of INDV by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, OAKTREE CAPITAL MANAGEMENT, based on the most recent SEC filings. INDV trades on the Nasdaq exchange and files with the SEC under CIK 1625297. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INDV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Indivior Pharmaceuticals, Inc. directly from SEC EDGAR. Indivior Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 53 and 70 since 2026, currently 58.5 — a declining long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about Indivior Pharmaceuticals, Inc.

Quirks, history, and lore behind INDV — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · listed on Nasdaq · headquartered in Virginia · focused entirely on addiction treatment.
2
The Numbers
Annual revenue in the range of roughly $1 billion, with a product portfolio that lives or dies on a single therapeutic category: opioid use disorder.
3
The History
The company was spun off from Reckitt Benckiser — yes, the cleaning-products giant — around 2014, taking its addiction medicine franchise with it as an independent entity.
4
The Secret
It has faced significant legal scrutiny over marketing practices, including a major U.S. Department of Justice settlement, making its history almost as troubled as the epidemic it treats.
5
The Lore
Its flagship treatment comes in a dissolvable film strip placed under the tongue — a delivery format so distinctive it helped define how doctors think about medication-assisted opioid treatment.
6
The Giveaway
The maker of Suboxone — the buprenorphine-naloxone film that became the standard of care for opioid dependence — and the company that fought (and lost) patent battles to keep generic rivals at bay.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving INDV's Business? Latest 10-Q Breakdown

✓ 29/29 datapoints verified

AI-extracted from Indivior Pharmaceuticals, Inc.'s 10-Q filed 2026-08-03 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net revenue grew 14% YoY to $343M on 22% SUBLOCADE growth in the US, while gross margin expanded to 85% even as the company discloses a pending all-stock merger with Supernus.

Biggest Revenue Drivers

Total U.S.$300M+17% YoY

Growth primarily driven by sales of SUBLOCADE in the U.S.

Rest of World$43M-7% YoY

Reflects exit from certain non-U.S. markets; company expects this trend to continue

Biggest Revenue Drivers

Total revenue: $343M+14% YoY

Total U.S.$300M+17% YoY

Growth primarily driven by sales of SUBLOCADE in the U.S.

Within Total U.S.

SUBLOCADE$238M+22% YoY

Driven by dispense unit volume growth (up 18%), gross-to-net benefits and favorable price mix

Sublingual & other (Film/other)$57M+10% YoY

Benefited from favorable Film gross-to-net adjustments, offset by decline in U.S. Film category share

PERSERIS$5M-35% YoY

Rest of World$43M-7% YoY

Reflects exit from certain non-U.S. markets; company expects this trend to continue

Largest Expense Items

Selling, general and administrative$122M-23% YoY

Decrease primarily driven by headcount reductions and cost savings related to corporate initiatives

Cost of sales$50M-3% YoY

Decrease attributable to a prior-year $10M SUBLOCADE inventory write-down, partly offset by ~$2M of inventory provisions tied to market exit activities

Research and development$12M-42% YoY

Reflects reduced R&D activity following decisions to cease Phase 3 development of INDV-6001 and not advance INDV-2000 internally

Margins: Gross margin rose to 85% from 83% a year ago, driven by SUBLOCADE volume growth and lower cost of sales, including a prior-year inventory write-down that did not recur.

Watch Items from the Filing

SUBLOCADE alone accounted for 74% of net revenue in Q2 2026, up from 69% a year earlier, deepening reliance on a single product.
Company entered an Agreement and Plan of Merger with Supernus on August 1, 2026 (all-stock merger of equals); a termination fee of $174M is payable by Indivior in certain circumstances.
Company ceased Phase 3 development of INDV-6001 and decided not to advance INDV-2000 internally, and states it is 'not currently pursuing any pipeline activities.'
Accrued litigation settlement expenses of $56M remain for opioid litigation, and the Dental MDL now covers approximately 1,967 cases naming ~26,307 plaintiffs.
Rest of World revenue declined 7% YoY to $43M due to exits from certain non-U.S. markets, a trend management expects to continue.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$343.0M

Net Income

Q2 2026

$122.0M

Free Cash Flow

Q2 2026

$222.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+4.3% YoY

$1.24BFY 2025

FY22 $901.0MFY23 $1.09BFY24 $1.19BFY25 $1.24B

Net Income

+2900.0% YoY

$210.0MFY 2025

FY22 $-44.0MFY23 $-126.0MFY24 $7.0MFY25 $210.0M

Operating Income

+589.5% YoY

$262.0MFY 2025

FY22 $-81.0MFY23 $-152.0MFY24 $38.0MFY25 $262.0M

EPS (Diluted)

+3180.0% YoY

$1.64FY 2025

FY22 $-0.32FY23 $-0.92FY24 $0.05FY25 $1.64

Total Assets

-8.7% YoY

$1.20BFY 2025

FY22 $1.77BFY23 $1.76BFY24 $1.32BFY25 $1.20B

Total Debt

-4.2% YoY

$319.0MFY 2025

FY22 —FY23 $240.0MFY24 $333.0MFY25 $319.0M

Op. Cash Flow

-175.0% YoY

$-27.0MFY 2025

FY22 $-4.0MFY23 $-300.0MFY24 $36.0MFY25 $-27.0M

Free Cash Flow

-1428.6% YoY

$-93.0MFY 2025

FY22 $-9.0MFY23 $-308.0MFY24 $7.0MFY25 $-93.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.24B +4.3%	$1.19B +8.7%	$1.09B +21.3%	$901.0M	—	—
Net Income	$210.0M +2900.0%	$7.0M +105.6%	$-126.0M -186.4%	$-44.0M	—	—
Operating Income	$262.0M +589.5%	$38.0M +125.0%	$-152.0M -87.7%	$-81.0M	—	—
EPS (Diluted)	$1.64 +3180.0%	$0.05 +105.4%	$-0.92 -187.5%	$-0.32	—	—
Total Assets	$1.20B -8.7%	$1.32B -25.1%	$1.76B -0.6%	$1.77B -3.4%	$1.83B	—
Total Debt	$319.0M -4.2%	$333.0M +38.8%	$240.0M	—	—	—
Operating Cash Flow	$-27.0M -175.0%	$36.0M +112.0%	$-300.0M -7400.0%	$-4.0M	—	—
Free Cash Flow	$-93.0M -1428.6%	$7.0M +102.3%	$-308.0M -3322.2%	$-9.0M	—	—

Get alerted when INDV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Indivior Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INDV

BlackRock, Inc.
$767.6M18,709,432 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$310.7M7,572,287 sh
OAKTREE CAPITAL MANAGEMENT LP
$251.4M6,127,212 sh
VANGUARD CAPITAL MANAGEMENT LLC
$225.5M5,495,486 sh
STATE STREET CORP
$204.8M4,992,071 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$189.4M4,615,816 sh
Two Seas Capital LP
$142.8M3,479,493 sh
MORGAN STANLEY
$139.3M3,395,702 sh
FRANKLIN RESOURCES INC
$136.1M3,316,358 sh
GEODE CAPITAL MANAGEMENT, LLC
$129.7M3,159,866 sh

Fund	Value	Shares
BlackRock, Inc.	$767.6M	18,709,432
VANGUARD PORTFOLIO MANAGEMENT LLC	$310.7M	7,572,287
OAKTREE CAPITAL MANAGEMENT LP	$251.4M	6,127,212
VANGUARD CAPITAL MANAGEMENT LLC	$225.5M	5,495,486
STATE STREET CORP	$204.8M	4,992,071
FULLER & THALER ASSET MANAGEMENT, INC.	$189.4M	4,615,816
Two Seas Capital LP	$142.8M	3,479,493
MORGAN STANLEY	$139.3M	3,395,702
FRANKLIN RESOURCES INC	$136.1M	3,316,358
GEODE CAPITAL MANAGEMENT, LLC	$129.7M	3,159,866

Companies Similar to INDV

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

SOLV

Solventum Corp

AI score

Similar quality profile · 6 shared holders

Madison Avenue Partners, LP CLARK ESTATES INC/NY Bridgewater Associates, LP

SHC

Sotera Health Co

AI score

Similar quality profile · 8 shared holders

Two Seas Capital LP OP Asset Management Ltd Elo Mutual Pension Insurance Co

TGTX

TG THERAPEUTICS, INC.

AI score

Similar quality profile · 11 shared holders

Soleus Capital Management, L.P.Bridgewater Associates, LP DIADEMA PARTNERS LP

PAHC

PHIBRO ANIMAL HEALTH CORP

AI score

Similar quality profile · 12 shared holders

OBERWEIS ASSET MANAGEMENT INC/LSV ASSET MANAGEMENT CVFG LLC

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 24 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.DRIEHAUS CAPITAL MANAGEMENT LLC OBERWEIS ASSET MANAGEMENT INC/

RIGL

RIGEL PHARMACEUTICALS INC

AI score

Similar quality profile · 11 shared holders

Soleus Capital Management, L.P.LSV ASSET MANAGEMENT Hennion & Walsh Asset Management, Inc.

GMED

GLOBUS MEDICAL INC

AI score

Similar quality profile · 8 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.Madison Avenue Partners, LP Soleus Capital Management, L.P.

ACAD

ACADIA PHARMACEUTICALS INC

AI score

Similar quality profile · 14 shared holders

JUPITER ASSET MANAGEMENT LTD MARTINGALE ASSET MANAGEMENT L P Hennion & Walsh Asset Management, Inc.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INDV on your watchlist

Track score changes the day Indivior Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INDV a good stock to buy?

13F Pro's AI-powered analysis of Indivior Pharmaceuticals, Inc. (INDV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INDV are available on the INDV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. INDV is classified as a mid company.

Which hedge funds own INDV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INDV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Indivior Pharmaceuticals, Inc.'s investment landscape.